{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:58:22Z","timestamp":1767707902965,"version":"3.48.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-025-04192-2","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:27:45Z","timestamp":1764588465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced ovarian cancer with malignant bowel obstruction treated with multidisciplinary therapy resulting in long progression-free survival: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Juan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangjing","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Zan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"1","key":"4192_CR1","volume":"2016","author":"SE Cousins","year":"2016","unstructured":"Cousins SE, Tempest E, Feuer DJ. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2016;2016(1):CD002764.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4192_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s43046-025-00286-y","volume":"37","author":"AA Marzuqi","year":"2025","unstructured":"Marzuqi AA, et al. Efficacy and safety of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a systematic review and updated meta-analysis. J Egypt Natl Canc Inst. 2025;37(1):28.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"4","key":"4192_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/jso.21388","volume":"100","author":"M Deraco","year":"2009","unstructured":"Deraco M, et al. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100(4):321\u20138.","journal-title":"J Surg Oncol"},{"key":"4192_CR4","first-page":"54","volume":"2","author":"PH Sugarbaker","year":"2013","unstructured":"Sugarbaker PH. Cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy. Transl Gastrointest Cancer. 2013;2:54\u201374.","journal-title":"Transl Gastrointest Cancer"},{"issue":"2","key":"4192_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s13193-016-0505-5","volume":"7","author":"SS Mehta","year":"2016","unstructured":"Mehta SS, Bhatt A, Glehen O. Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol. 2016;7(2):139\u201351.","journal-title":"Indian J Surg Oncol"},{"issue":"3","key":"4192_CR6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ygyno.2019.07.003","volume":"154","author":"L Xiang","year":"2019","unstructured":"Xiang L, Ye S, Yang H. Total pelvic peritonectomy for ovarian cancer with extensive peritoneal carcinomatosis in pelvic cavity. Gynecol Oncol. 2019;154(3):651\u20132.","journal-title":"Gynecol Oncol"},{"key":"4192_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ejogrb.2020.05.058","volume":"251","author":"I Kyriazanos","year":"2020","unstructured":"Kyriazanos I, et al. Total extraperitoneal access for parietal peritonectomy for peritoneal surface malignancy: the \u201ccocoon\u201d technique. Eur J Obstet Gynecol Reprod Biol. 2020;251:258\u201362.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"4192_CR8","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.2147\/IJWH.S366680","volume":"14","author":"E Gonzalez-Ochoa","year":"2022","unstructured":"Gonzalez-Ochoa E, et al. Inoperable bowel obstruction in ovarian cancer: Prevalence, impact and management challenges. Int J Womens Health. 2022;14:1849\u201362.","journal-title":"Int J Womens Health"},{"issue":"1","key":"4192_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jpainsymman.2023.09.014","volume":"67","author":"M Walter","year":"2024","unstructured":"Walter M, et al. Palliative management of inoperable malignant bowel obstruction: prospective, open label, phase 2 study at an NCI comprehensive cancer center. J Pain Symptom Manage. 2024;67(1):20\u20136.","journal-title":"J Pain Symptom Manage"},{"key":"4192_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144213","author":"R Toth","year":"2024","unstructured":"Toth R, et al. Management of malignant bowel obstruction in patients with gynaecological cancer: a systematic review. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13144213.","journal-title":"J Clin Med"},{"issue":"1 Suppl","key":"4192_CR11","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jpainsymman.2007.04.011","volume":"34","author":"T Anthony","year":"2007","unstructured":"Anthony T, et al. Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manage. 2007;34(1 Suppl):S49\u201359.","journal-title":"J Pain Symptom Manage"},{"issue":"12","key":"4192_CR12","doi-asserted-by":"publisher","first-page":"7555","DOI":"10.1245\/s10434-021-09831-0","volume":"28","author":"SB Bateni","year":"2021","unstructured":"Bateni SB, et al. Chemotherapy after diagnosis of malignant bowel obstruction is associated with superior survival for medicare patients with advanced malignancy. Ann Surg Oncol. 2021;28(12):7555\u201363.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4192_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ygyno.2013.02.002","volume":"129","author":"E Diver","year":"2013","unstructured":"Diver E, et al. Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement. Gynecol Oncol. 2013;129(2):332\u20135.","journal-title":"Gynecol Oncol"},{"issue":"e3","key":"4192_CR14","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1136\/bmjspcare-2021-003492","volume":"13","author":"M Patterson","year":"2024","unstructured":"Patterson M, et al. Inoperable malignant bowel obstruction: palliative interventions outcomes - mixed-methods systematic review. BMJ Support Palliat Care. 2024;13(e3):e515\u201327.","journal-title":"BMJ Support Palliat Care"},{"issue":"2","key":"4192_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/cam4.587","volume":"5","author":"J Chouhan","year":"2016","unstructured":"Chouhan J, et al. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med. 2016;5(2):239\u201347.","journal-title":"Cancer Med"},{"issue":"2","key":"4192_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(20)30591-X","volume":"22","author":"RD Morgan","year":"2021","unstructured":"Morgan RD, et al. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncol. 2021;22(2):277\u201388.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4192_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1\u20136.","journal-title":"N Engl J Med"},{"key":"4192_CR18","doi-asserted-by":"publisher","first-page":"p1867238","DOI":"10.1155\/2018\/1867238","volume":"2018","author":"YC Lee","year":"2018","unstructured":"Lee YC, et al. Malignant bowel obstruction in advanced gynecologic cancers: an updated review from a multidisciplinary perspective. Obstet Gynecol Int. 2018;2018:p1867238.","journal-title":"Obstet Gynecol Int"},{"issue":"5","key":"4192_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/ijgc-2020-002133","volume":"31","author":"M Tigert","year":"2021","unstructured":"Tigert M, et al. Factors impacting length of stay and survival in patients with advanced gynecologic malignancies and malignant bowel obstruction. Int J Gynecol Cancer. 2021;31(5):727\u201332.","journal-title":"Int J Gynecol Cancer"},{"key":"4192_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/frhem.2025.1609642","author":"J Jerez","year":"2025","unstructured":"Jerez J, Hernandez C, Hill CN. Understanding therapy-related AML: genetic insights and emerging strategies for high-risk patients. Front Hematol. 2025. https:\/\/doi.org\/10.3389\/frhem.2025.1609642.","journal-title":"Front Hematol"},{"key":"4192_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30360-4","author":"P Morice","year":"2021","unstructured":"Morice P, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021. https:\/\/doi.org\/10.1016\/S2352-3026(20)30360-4.","journal-title":"Lancet Haematol"},{"key":"4192_CR22","first-page":"100","volume":"23","author":"J Liu","year":"2025","unstructured":"Liu J, Matulonis UA. Update on PARP inhibitors for the treatment of ovarian cancer. Clinical advances in hematology & oncology H&O. 2025;23:100\u201310.","journal-title":"Clinical advances in hematology & oncology H&O"},{"key":"4192_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13071525","author":"D Papageorgiou","year":"2025","unstructured":"Papageorgiou D, et al. Management of advanced ovarian cancer: current clinical practice and future perspectives. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13071525.","journal-title":"Biomedicines"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-04192-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-025-04192-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-04192-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:52:51Z","timestamp":1767707571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-025-04192-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4192"],"URL":"https:\/\/doi.org\/10.1186\/s12905-025-04192-2","relation":{},"ISSN":["1472-6874"],"issn-type":[{"type":"electronic","value":"1472-6874"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"9 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This report was reviewed and approved by the Ethics Committee of People\u2019s Hospital of Leshan, Sichuan, China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for the publication of this case report and any accompanying, potentially identifiable images or data were obtained from the patient\u2019s daughter, as the patient had passed away prior to manuscript preparation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}